Drugs / DWP212525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06736587 | Dec 2024 → Dec 2026 expected | autoimmune disease | Daewoong Pharmaceutical Co. LTD. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-11-12 | Daewoong Pharmaceutical Co. LTD. | Results Daewoong Pharmaceutical released a research result of an autoimmune disease candidate substance, ‘DWP212525’ for the first time in American College of Rheumatology. daewoong.co.kr ↗
DWP212525, which inhibited the activity of both target subjects in a cell experiment, showed improvement in PEMPHIGUS, a rare autoimmune skin disease, and inhibitory effect on disease-causing factors in experiments using mice. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-11-12 | Daewoong Pharmaceutical Co. LTD. | Daewoong Pharmaceutical released a research result of an autoimmune disease candidate substance, ‘DWP212525’ for the first time in American College of Rheumatology. daewoong.co.kr ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWP212525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736587 ↗ |